Background and Aims: Thyroid hormones influence all metabolic processes in the body Diabetes mellitus (DM) and thyroid dysfunction (TD) are among the most prevalent endocrine disorders Adipsin is an adipokine that may link increased fat mass and adipose tissue dysfunction to obesity-related cardiometabolic diseases. To study whether adipsin may be a diagnostic biomarker of thyroid diseases, and follow up the progression of diabetes mellitus in these patients, and whether these patients are at risk of cardiovascular diseases.
Methods: The current study included 130 women with age’s range 25-55 years’ old, 100 of them are female’s patients with thyroid dysfunction and 30 females as a control (C). All patients were classifying into four groups: (25) women patients with hypothyroidism as G1, (25) hypothyroidism women patients with DM as G2, (25) women patients with hyperthyroidism as G3, and (25) hyperthyroidism women patients with DM as G4.
Results: The study found a significant increase in adipsin levels in all patients’ groups compared to control. There were an important elevation in TG, Chol, and LDL-ch levels in G2 and G3, also TG was significant increase in G3 and G4, in addition a significant elevation in LDL-ch in G4.While there were a significant decrease in HDL-ch levels in all patient groups.
Conclusions: The current study suggests that adipsin may be a diagnostic and follow-up marker of DM in thyroid disease patients. Compared to hyperthyroidism, patients with hypothyroidism may be at risk for cardiovascular diseases. Additionally, adipsin may be considered a diagnostic marker for thyroid dysfunction.